HTS and Secondary Screening | Labcyte Inc.

HTS and SECONDARY SCREENING

Eliminate pipette tip-related issues with direct dilution

HOME | APPLICATIONS | HTS and Secondary Screening

Discover the Right Drugs with Improved Transfer Performance

Many scientific publications have shown that discoveries made using the Echo liquid handler would have been impossible with traditional methods — thanks in part to direct dilution and the elimination of pipette tip-related issues.

Echo 525 Liquid Handler Echo® 555 LIQUID HANDLER

Highly Accurate Data and Volume Tracking

Our patented DMSO concentration monitoring helps ensure accurate data tracking, while the Echo liquid handler provides volume tracking and the advantages of touchless dispensing for all assay components. Coupled with Labcyte Automation , DMSO concentration monitoring delivers an extremely high level of productivity.

Key Benefits

  • Excellent retention of promising leads through touchless dispensing and direct dilution
  • Dependable dispensing of all assay components, without user intervention
  • Seamless automation of workflows for the greatest possible throughput


CASE STUDIES

Our patented DMSO concentration monitoring helps ensure accurate data tracking, while the Echo Liquid Handler provides volume tracking and the advantages of touchless dispensing for all assay components. Coupled with Labcyte automation options, DMSO concentration monitoring delivers an extremely high level of productivity.


AstraZeneca — 259x More Potent

AstraZeneca demonstrated better compound potency when transferring directly with an Echo Liquid Handler instead of a serial dilution process1.

Compount Number Echo® Liquid Handler Traditional Liquid Handler
4 0.003 0.146
5 0.002 0.553
6 0.007 0.973
7 0.003 0.778
8 0.004 0.445
9 0.052 0.170
10 0.064 0.817
11 0.486 3.03

A recent patent filing by AstraZeneca indicated the Echo Liquid Handler and its direct dilution process were critical to the discovery of its patented therapy. The filing includes data that shows a multiple order of magnitude difference in IC50 results when compared to traditional methods. Without the Echo Liquid Handler, these therapies may have been missed. What therapies could you be missing? Read the patent filing for more details.


32% More Active Compounds Found

In a screen of 975 compounds, Bristol-Myers Squibb found 108 more hits when using the Echo Liquid Handler1.

46% Increase Using Echo Liquid Transfer

Bristol-Myers Squibb demonstrated fewer false negatives in IC50 assays prepared using the Echo Liquid Handler vs. traditional aqueous serial dilutions. The results revealed 110 compounds that showed significant activity when diluted using the Echo platform. They would have been eliminated as ineffective when diluted using traditional serial dilution. Closer examination revealed that false negatives are often caused by the loss of hydrophobic compounds adhering to pipette tips and dilution vessels. Without an Echo Liquid Handler, you may be missing your best leads. Read the report.



1    Barlaam, B.C. et al., U.S. Patent 7,718,653, 2010.
2   Spicer, T. et al., Presentation at Drug Discovery Technology, Boston, MA, August 2005.